Aurobindo Pharma Q1 Results Review - Margins On Course For Gradual Improvement: ICICI Securities

ICICI Securities Report

Aurobindo Pharma Ltd.’s Q1 FY25 result came in short of our expectations amid lower U.S. sales and a surge in costs. U.S. sales dipped 1.4% QoQ as supplies from Eugia unit three were lower ($15–20 million impact) due to Official action indiacted at plant; over-the-counter biz saw a seasonal dip. The company incurred a cost of ~Rs 1 billion from plant remediation ($9 million) and overheads of new plants (Rs 250 million); adjusting for it, Ebitda margin was at 22.7%.

Remediation cost should ease to ~$2 million in Q2 FY25 while operational overheads are likely absorbed gradually. Development of biosimilars is on track. Its India foray is envisaged in H2 FY25 and Europe/U.S. in FY26/27.

Aurobindo may soon re-initiate the listing of Eugia. FY25 Ebitda guidance of 21–22% may be revised post Q2 FY25. We downgrade to Add and raise the target price to Rs 1,620, based on 18 times FY26E earnings per share.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.